USRE36331E - Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them - Google Patents

Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them Download PDF

Info

Publication number
USRE36331E
USRE36331E US09035028 US3502898A USRE36331E US RE36331 E USRE36331 E US RE36331E US 09035028 US09035028 US 09035028 US 3502898 A US3502898 A US 3502898A US RE36331 E USRE36331 E US RE36331E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
carnitine
acid
mm
blood
storage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09035028
Inventor
Arduino Arduini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma-Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion

Abstract

Solutions which contain L-carnitine and alkanoyl L-carnitine are useful for stabilizing blood for transfusions.

Description

.Iadd.CONTINUING APPLICATION DATA

This application is a Reissue application of Ser. No. 08/253,275, filed Jun. 2, 1994, U.S. Pat. No. 5,496,821. .Iaddend.

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

The present invention consists in a new non-therapeutic use of L-carnitine, alkanoyl L-carnitines and their pharmacologically acceptable salts as preservative agents for blood transfusions.

The present invention also consists in new stabilizing solutions for the storage of blood containing L-carnitine, alkanoyl L-carnitines or their pharmacologically acceptable salts.

What is meant by alkanoyl L-carnitines are acetyl, propionyl, butyryl, isobutyryl, valeryl and isovaleryl L-carnitine. Hereinafter, for reasons of simplicity, we shall refer only to L-carnitine, in the understanding, however, that the description also applies to the above-mentioned alkanoyl L-carnitines and their pharmacologically acceptable salts.

As is well known, L-carnitine is necessary for the translocation of fatty acids within the mitichondria where betaoxidation takes place.

Various uses of L-carnitine are known, but all of these are of a therapeutic nature. For instance, L-carnitine is used in the cardiovascular field for the treatment of acute and chronic myocardial ischaemia, angina pectoris, heart failure and cardiac arrhythmias.

In the nephrological field, L-carnitine is administered to chronic uraemics undergoing regular haemodialytic treatment to combat myasthenia and the onset of muscular cramps.

Other therapeutic uses have to do with the normalization of the HDL:LDL+VLDL ratio and total parenteral nutrition. There is, however, no relationship between the known therapeutic uses of L-carnitine mentioned previously and the use envisaged in the present invention.

It is well known that the essential factors for good storage of blood in the liquid state are the temperature and the composition of the stabilizing solution.

The temperature must be such as to allow a reduction of the metabolic activity of the erythrocytes without damaging them. The optimal temperature is 4° C.±2° C.

The stabilizing solutions must be able to make the blood unclottable, to reduce the glycolytic activity of the red blood cells and, at the same time, permit such activity by providing an adequate substrate.

The efficacy of a stabilizing solution is assessed by observing both the alterations arising in the erythrocytes in vitro and their survival in vivo, after variable periods of storage at optimal temperature.

The alterations to the erythrocytes in vitro can be checked by evaluating the amount of haemoglobin released by the erythrocytes, their osomotic and mechanical fragility, the changes in their shape and volume and the chemical changes they undergo.

The stabilizing solutions used to date do not allow good storage of blood for more than 14 to 21 days.

For instance, if the blood is collected in ACD (citric acid-sodium citrate-dextrose), one of the most widely used stabilizing solutions in the past, and transfused after 14 or 21 days of storage, the in-vivo survival rates of erythrocytes 24 h after transfusion are 90 and 80%, respectively; it is also well known that the red blood cells that remain in circulation 24 h after transfusion have a survival rate equal to that of fresh blood.

During storage, erythrocytes undergo alterations with formation of spherocytes and burr cells. The erythrocytes swell and lose potassium and haemoglobin, which then increases in the plasma. At the same time there is a reduction in 2,3-DPG (2,3-diphosphoglycerate) and thus an increase in the affinity of haemoglobin for oxygen, which is released to tissues in smaller amounts.

The alterations of erythrocytes stored in ACD may be at least partly corrected by adding phosphate to the stabilizing solution. Thus CPD (citrate-phsophate-dextrose) solutions have come to be used for the storage of blood and are now the ones most commonly employed The addition of phosphate gives rise to the maintenance of a higher level of 2,3-DPG and thus a lower affinity of haemoglobin for oxygen. However, the in-vivo survival of erythrocytes stored in CPD is little better, if not indeed identical to that of erythrocytes stored in ACD.

SUMMARY OF THE INVENTION

It has now been found that the addition of L-carnitine or of one of its pharmacologically acceptable salts to the usual stabilizing solutions for the storage of blood for transfusions has the effect of dramatically improving in-vitro survival of erthrocytes and of reducing the formation of spherocytes and burr cells and the loss of haemoglobin in the plasma. As a result of these beneficial effects, the period of good storage of blood for transfusion purposes is more than doubled compared to traditional solutions.

Thus, the invention described herein consists in the use of L-carnitine and its pharmacologically acceptable salts for the production of stabilizing solutions for the storage of blood for transfusions.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Viewed from a different angle, the invention also consists in stabilizing solutions for the storage of blood for transfusion characterized by the fact that they contain L-carnitine or one of its pharmacologically acceptable salts.

What is meant by pharmacologically acceptable salts of L-carnitine, apart from the L-carnitine internal salt, is any L-carnitine salt with an acid which does not give rise to unwanted side effects. These acids are well known to pharmacologists and to experts in pharmacy.

Non-exclusive examples of such salts are chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate and acid fumarate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

These solutions are characterized by the fact that they contain 0.5-10.0 mM/L, and preferably 4-6 mML of L-carnitine or an equivalent amount of one of its pharmacologically acceptable salts.

An example of a stabilizing solution according to the invention is composed of:

______________________________________Glucose               80-120 mM/LMannitol              40-60 mM/LK.sub.2 HPO.sub.4     24-28 mM/LKH.sub.2 PO.sub.4     12-16 mM/LPotassium citrate     15-20 mM/LL-carnitine, internal salt                 4-6 mM/L______________________________________
BRIEF DESCRIPTION OF THE DRAWINGS

The efficacy of L-carnitine in the use envisaged in this invention is verified by numerous studies, one of which is reported here below with reference to the attached diagrams, where:

FIG. 1 is a graph representing the osomotic fragility of eythrocytes as a function of storage time (expressed in weeks);

FIG. 2 is a graph representing the haemoglobin concentration (in mg/dL) in the storage medium as a function of storage time (expressed in weeks);

FIG. 3 is a graph representing the percentage of burr cells in the storage medium as a function of storage time (expressed in weeks).

EXAMPLES

Admitted to this study were volunteers who were habitual blood donors and who were perfectly healthy at the time the blood samples were taken. The blood samples were collected in special quadruple bags normally used for blood storage Baxter, Fenwal Division, La Chatre, France) containing CPDA-1 (CPDA-1 composition: 110 mM glucose; 55 mM mannitol; 25.8 mM K2 HPO4 ; 14.7 mM KH2 PO4 ; 17.9 mM potassium citrate), an iso-osmolar fluid commonly used for the storage of blood at 5° C. The blood was poured into the above-mentioned bags by means of a centrifuge which allowed the formed elements of the haematic mass to be separated from the erythrocytes. In addition to the above-mentioned CPDA-1, some of the bags contained L-carnitine, which was always introduced under conditions of maximum sterility. The ratio of the volume of the storage fluid to the volume of the erythrocytes was close to 1:1. The bags were then placed in refrigerators at a constant temperature of 5° C.

In the course of storage, aliquots of erythrocytes were collected at weekly intervals for the purpose of conducting a number of microscopic and biochemical examinations. The eryrocyte suspension was immediately examined under a phase-contrast microscope to estimate the percentage content of burr cells, which are pathological erythrocytes with a star-type morphology. Later, the eryrthocyte suspension was centrifuged, and the buffy coat was used to determine the haemoglobin content according to a method involving the derivatization of the latter to cyanomethaemoglobin (International Committee for Standardization in Haematology, S. Clin. Pathol. (1978), 31:139-145). The haemoglobin content measured is an indicator of the degree of haemolysis the erythrocyte undergoes in the course of storage in the bags. Lastly, erythrocyte osmotic fragility was evaluated according to the method of Dacie and Lewis (Dacie J. V. and Lewis S. M., Practical Haematology, New York: Churchill Livingstone, 1984: 152-6). The osmotic fragility was calculated as the amount of sodium chloride necessary (in mM/L) to obtain 50% haemolysis.

Claims (10)

I claim:
1. A method for stabilizing blood for transfusion, comprising mixing blood with a solution, said solution comprising L-carnitine, alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucoses phosphate, tartrate, and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine.
3. The method of claim 1, wherein said solution comprises:
______________________________________Glucose               80-120 mM/LMannitol              40-60 mM/LK.sub.2 HPO.sub.4     24-28 mM/LKH.sub.2 PO.sub.4     12-16 mM/LPotassium citrate     15-20 mM/LL-carnitine, internal salt                 4-6 mM/L.______________________________________
4. The method of claim 1, wherein said solution comprises 4-6 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt.
5. The method of claim 1, wherein said solution is mixed with said blood in a ratio to obtain a ratio of volume of solution to volume of erythrocytes of about 1:1.
6. A transfusion bag which comprises:
(a) a sample of whole blood;
(b) a preservative-anticoagulant solution; and
(c) 4-6 mM/L of L-carnitine, alkanoyl L-carnitine or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucoses phosphate, tartrate, and acid tartrate.
7. The transfusion bag of claim 6, wherein said preservative-anticoagulant solution is selected from ACD, CPD and CPDA-1.
8. The transfusion bag of claim 6, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine. .Iadd.
9. A method for stabilizing a composition for transfusion comprising erythrocytes, said method comprising mixing said composition with a solution, said solution comprising L-carnitine, alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof. .Iaddend..Iadd.10. A transfusion bag which comprises:
(a) a composition comprising erythrocytes;
(b) a preservative-anticoagulant solution; and
(c) 4-6 mM/L of L-carnitine, alkanoyl L-carnitine or pharmaceutically acceptable salt thereof, wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartic acid, acid citrate, acid phosphate, fumarate, acid fumarate, maleate, acid maleate, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate, and wherein said solution comprises 0.5-10.0 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt thereof. .Iaddend..Iadd.11. The method of claim 9, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine.
.Iaddend..Iadd.12. The method of claim 9, wherein said solution comprises:
______________________________________Glucose               80-120 mM/LMannitol              40-60 mM/LK.sub.2 HPO.sub.4     24-28 mM/LKH.sub.2 PO.sub.4     12-16 mM/LPotassium citrate     15-20 mM/LL-carnitine, internal salt                 4-6 mM/L.______________________________________
.Iaddend..Iadd.13. The method of claim 9, wherein said solution comprises 4-6 mM/L of said L-carnitine, said alkanoyl L-carnitine, or said pharmaceutically acceptable salt. .Iaddend..Iadd.14. The transfusion bag of claim 10, wherein said preservative-anticoagulant solution is selected from ACD, CPD and CPDA-1. .Iaddend..Iadd.15. The transfusion bag of claim 10, wherein said alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, isobutyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine. .Iaddend.
US09035028 1993-06-02 1998-03-05 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them Expired - Lifetime USRE36331E (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITRM930364 1993-06-02
ITRM93A0364 1993-06-02
US08253275 US5496821A (en) 1993-06-02 1994-06-02 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them
US09035028 USRE36331E (en) 1993-06-02 1998-03-05 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09035028 USRE36331E (en) 1993-06-02 1998-03-05 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08253275 Reissue US5496821A (en) 1993-06-02 1994-06-02 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Publications (1)

Publication Number Publication Date
USRE36331E true USRE36331E (en) 1999-10-05

Family

ID=11401790

Family Applications (2)

Application Number Title Priority Date Filing Date
US08253275 Expired - Lifetime US5496821A (en) 1993-06-02 1994-06-02 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them
US09035028 Expired - Lifetime USRE36331E (en) 1993-06-02 1998-03-05 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08253275 Expired - Lifetime US5496821A (en) 1993-06-02 1994-06-02 Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Country Status (6)

Country Link
US (2) US5496821A (en)
EP (1) EP0627161B1 (en)
JP (1) JP3573791B2 (en)
DE (2) DE69413120T2 (en)
DK (1) DK0627161T3 (en)
ES (1) ES2122214T3 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156990A1 (en) * 2001-06-14 2004-08-12 Arduino Arduini Solution for the storage and perfusion of organs awaiting transplantation
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20060212020A1 (en) * 2002-10-10 2006-09-21 Lynne Rainen Sample collection system with caspase inhibitor
US7309468B2 (en) 2002-05-13 2007-12-18 Becton, Dickinson And Company Protease inhibitor sample collection system

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403124B1 (en) * 1997-04-16 2002-06-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
CA2332986C (en) 1998-05-26 2009-09-08 Lifecell Corporation Cryopreservation of human red blood cells
WO2001026649A1 (en) * 1999-10-11 2001-04-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use
GB0001172D0 (en) * 2000-01-20 2000-03-08 Res Del International Limited Physiological medium for perfusing, preserving and storing isolated cell tissue and organ samples
EP1659862A2 (en) * 2003-08-04 2006-05-31 Human Biosystems Preservation of blood cells
KR101296479B1 (en) * 2004-07-13 2013-08-13 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. Use of l-carnitine and glucose for the treatment of cardiovascular diseases
US8968992B2 (en) * 2008-03-21 2015-03-03 Fenwal, Inc. Red blood cell storage medium for extended storage
US8871434B2 (en) * 2008-03-21 2014-10-28 Fenwal, Inc. Red blood cell storage medium for extended storage
WO2011049709A1 (en) 2009-10-23 2011-04-28 Fenwal, Inc. Methods and systems for providing red blood cell products with reduced plasma
JP5824950B2 (en) * 2011-08-08 2015-12-02 ソニー株式会社 Blood analyzer and blood analyzing method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434160A (en) * 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4839159A (en) * 1988-02-08 1989-06-13 Topicarn, Inc. Topical L-carnitine composition
US4968714A (en) * 1989-02-21 1990-11-06 Bayer Aktiengesellschaft Fungicidal substituted 3-amino-2-pyrazolin-5-ones, compositions and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639532A (en) *
DE2532183C3 (en) * 1975-07-18 1982-03-04 Behringwerke Ag, 3550 Marburg, De
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0517125A1 (en) * 1991-06-05 1992-12-09 SIGMA TAU Industrie Farmaceutiche Riunite S.p.A. Use of propionyl L-carnitine for regaining muscle tone in immobilised patients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434160A (en) * 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4839159A (en) * 1988-02-08 1989-06-13 Topicarn, Inc. Topical L-carnitine composition
US4968714A (en) * 1989-02-21 1990-11-06 Bayer Aktiengesellschaft Fungicidal substituted 3-amino-2-pyrazolin-5-ones, compositions and use

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156990A1 (en) * 2001-06-14 2004-08-12 Arduino Arduini Solution for the storage and perfusion of organs awaiting transplantation
US7989158B2 (en) 2001-06-14 2011-08-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Solution containing carnitine for the storage and perfusion of organs awaiting transplantation
US8007993B2 (en) 2001-06-14 2011-08-30 Sigma—Tau Industrie Farmaceutiche Riunite, S.p.A. Method for storage and perfusion of organs using a solution comprising L-carnitine and isovaleryl L-carnitine
US20080166695A1 (en) * 2001-06-14 2008-07-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Solution for the storage and perfusion of organs awaiting transplantation
US7422844B2 (en) * 2001-06-14 2008-09-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Solution for the storage and perfusion of organs awaiting transplantation
US20080241001A1 (en) * 2002-05-13 2008-10-02 Becton, Dickinson And Company Protease Inhibitor Sample Collection System
US7645425B2 (en) 2002-05-13 2010-01-12 Becton, Dickinson And Company Protease inhibitor sample collection system
US7309468B2 (en) 2002-05-13 2007-12-18 Becton, Dickinson And Company Protease inhibitor sample collection system
US20060212020A1 (en) * 2002-10-10 2006-09-21 Lynne Rainen Sample collection system with caspase inhibitor
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid

Also Published As

Publication number Publication date Type
DE69413120D1 (en) 1998-10-15 grant
US5496821A (en) 1996-03-05 grant
DK0627161T3 (en) 1999-06-07 grant
EP0627161A1 (en) 1994-12-07 application
JPH0748329A (en) 1995-02-21 application
JP3573791B2 (en) 2004-10-06 grant
EP0627161B1 (en) 1998-09-09 grant
ES2122214T3 (en) 1998-12-16 grant
DK627161T3 (en) grant
DE69413120T2 (en) 1999-02-11 grant

Similar Documents

Publication Publication Date Title
Cantu et al. Experimental prevention of cerebral vasculature obstruction produced by ischemia
Uraizee et al. Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs.
Iseri et al. Magnesium and potassium therapy in multifocal atrial tachycardia
Murry et al. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
US5130230A (en) Blood substitute
Quillen et al. Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries.
Shug et al. Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia
Baue et al. Hemodynamic and metabolic effects of Ringer's lactate solution in hemorrhagic shock.
Seelig Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations—magnesium and chloride loss in refractory potassium repletion
Orofino et al. Epidemiology of symptomatic hypotension in hemodialysis: Is cool dialysate beneficial for all patients?
Prasad et al. Increased oxygen free radical activity in patients on cardiopulmonary bypass undergoing aortocoronary bypass surgery
Jolly et al. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.
Rouslin et al. Effects of oligomycin and acidosis on rates of ATP depletion in ischemic heart muscle
Webb et al. Suspended animation of the heart with metabolic inhibitors. Effect of magnesium sulfate or fluoride and adrenochrome in rats.
Powell et al. The protective effect of hyperosmotic mannitol in myocardial ischemia and necrosis.
US5571801A (en) Plasma expander and blood substitute
US4546095A (en) Use of fructose-1,6-diphosphate for treating myocardial infarction
Martin et al. Acute limited normovolemic hemodilution: a method for avoiding homologous transfusion
US4112070A (en) Blood preservation system
Pappius et al. The effects of rapid hemodialysis on brain tissues and cerebrospinal fluid of dogs
Duhm et al. On the mechanisms of the hypoxia-induced increase of 2, 3-diphosphoglycerate in erythrocytes
Wei et al. Inhibition by free radical scavengers and by cyclooxygenase inhibitors of pial arteriolar abnormalities from concussive brain injury in cats.
PoPIo et al. Identification and description of separate mechanisms for two components of renografin cardiotoxicity.
Laks et al. Acute hemodilution: its effect on hemodynamics and oxygen transport in anesthetized man
US4938961A (en) Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

REMI Maintenance fee reminder mailed